CJC-1295 Research
Long-Acting GHRH Analog
growth hormone signaling
Immune Support, Training and Energy
Informations éducatives uniquement. Les utilisations expérimentales peuvent ne pas avoir l'approbation de la FDA. Pas un avis médical ou un plan de traitement.
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) engineered for an extended pharmacokinetic profile. Through a drug affinity complex (DAC) technology that enables albumin binding, it achieves a prolonged half-life compared to native GHRH. It is studied for its role in sustained growth hormone axis stimulation and downstream signaling pathway research.
Domaines de recherche
GHRH Receptor Signaling
Research examines CJC-1295's agonism at pituitary GHRH receptors, investigating its downstream activation of adenylyl cyclase signaling, cAMP production, and somatotroph stimulation pathway research.
Pharmacokinetic & Half-Life Research
Studies investigate the DAC (drug affinity complex) mechanism that enables albumin binding, exploring how extended receptor exposure affects GH pulse dynamics compared to native GHRH signaling.
Growth Hormone Axis Stimulation
Researchers study its effects on sustained GH secretion signaling over multi-day dosing intervals, exploring pituitary somatotroph responsiveness and GH axis feedback pathway research.
IGF-1 Downstream Pathway Research
Studies examine its downstream effects on hepatic IGF-1 production, IGF-binding protein signaling, and tissue-level anabolic pathway research associated with sustained GHRH receptor activation.
Investigational compound. Not FDA-approved. Often studied in combination with Ipamorelin. Not medical advice.
Des questions sur CJC-1295 ?
Demandez une consultation gratuite pour poser des questions et en savoir plus sur ce domaine de recherche.
Demander une consultation gratuite